• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score.

作者信息

D'Agostino Mattia, Larocca Alessandra, Offidani Massimo, Liberati Anna Marina, Gaidano Gianluca, Petrucci Maria Teresa, Derudas Daniele, Capra Andrea, Zambello Renato, Cascavilla Nicola, de Fabritiis Paolo, Innao Vanessa, Bonello Francesca, Patriarca Francesca, Benevolo Giulia, Giuliani Nicola, Aitoro Gabriele, Guglielmelli Tommasina, Di Raimondo Francesco, Corradini Paolo, Musto Pellegrino, Hájek Roman, Sonneveld Pieter, Boccadoro Mario, Bringhen Sara

机构信息

Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy.

Clinica di Ematologia, AOU Ospedali Riuniti di Ancona, Ancona, Italy.

出版信息

Blood Cancer J. 2021 Apr 12;11(4):73. doi: 10.1038/s41408-021-00464-w.

DOI:10.1038/s41408-021-00464-w
PMID:33846296
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8041817/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8833/8041817/73cd5459b61d/41408_2021_464_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8833/8041817/73cd5459b61d/41408_2021_464_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8833/8041817/73cd5459b61d/41408_2021_464_Fig1_HTML.jpg

相似文献

1
Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score.无老年功能障碍的老年初诊多发性骨髓瘤患者：年龄>80岁在国际骨髓瘤工作组衰弱评分中的作用
Blood Cancer J. 2021 Apr 12;11(4):73. doi: 10.1038/s41408-021-00464-w.
2
Prevalence of geriatric impairments and frailty categorization among real-world patients with multiple myeloma: a prospective cohort study (MFRAIL).真实世界多发性骨髓瘤患者老年综合征和衰弱分类的流行情况：一项前瞻性队列研究（MFRAIL）。
Leuk Lymphoma. 2024 Aug;65(8):1167-1174. doi: 10.1080/10428194.2024.2340052. Epub 2024 Apr 16.
3
Comprehensive geriatric assessment in newly diagnosed older myeloma patients: a multicentre, prospective, non-interventional study.新诊断老年多发性骨髓瘤患者的全面老年评估：一项多中心、前瞻性、非干预性研究。
Age Ageing. 2022 Jan 6;51(1). doi: 10.1093/ageing/afab211.
4
A comparison of three different approaches to defining frailty in older patients with multiple myeloma.三种不同方法用于定义老年多发性骨髓瘤患者虚弱状态的比较。
J Geriatr Oncol. 2020 Mar;11(2):311-315. doi: 10.1016/j.jgo.2019.07.004. Epub 2019 Jul 17.
5
Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores.老年多发性骨髓瘤患者的评估：国际骨髓瘤工作组（IMWG）评分的验证及与其他常见合并症评分的比较
Haematologica. 2016 Sep;101(9):1110-9. doi: 10.3324/haematol.2016.148189. Epub 2016 Jun 16.
6
Performance of the International Myeloma Working Group myeloma frailty score among patients 75 and older.75 岁及以上患者中国际骨髓瘤工作组骨髓瘤虚弱评分的表现。
J Geriatr Oncol. 2019 May;10(3):486-489. doi: 10.1016/j.jgo.2018.10.010. Epub 2018 Nov 22.
7
Development of a Medicare Health Outcomes Survey Deficit-Accumulation Frailty Index and Its Application to Older Patients With Newly Diagnosed Multiple Myeloma.医疗保险健康结果调查累积缺陷衰弱指数的开发及其在新诊断的多发性骨髓瘤老年患者中的应用。
JCO Clin Cancer Inform. 2018;2. doi: 10.1200/CCI.18.00043. Epub 2018 Jul 25.
8
Comparison of Frailty Scores in Newly Diagnosed Patients with Multiple Myeloma: A Review.新诊断多发性骨髓瘤患者衰弱评分的比较：一项综述
J Frailty Aging. 2019;8(4):215-221. doi: 10.14283/jfa.2019.25.
9
Frailty in Older Adults With Multiple Myeloma: A Study of US Veterans.老年人多发性骨髓瘤的脆弱性：一项对美国退伍军人的研究。
JCO Clin Cancer Inform. 2020 Feb;4:117-127. doi: 10.1200/CCI.19.00094.
10
The Effects of Second Primary Malignancies and Frailty on Overall Survival and Mortality in Geriatric Turkish Patients with Multiple Myeloma.老年土耳其多发性骨髓瘤患者第二原发性恶性肿瘤和虚弱对总生存和死亡率的影响。
Curr Oncol. 2023 Jun 9;30(6):5615-5630. doi: 10.3390/curroncol30060423.

引用本文的文献

1
Prognostic Frailty-Based Determinants of Long-Term Mortality in Older Patients with Newly Diagnosed Multiple Myeloma.基于衰弱的新诊断多发性骨髓瘤老年患者长期死亡率的预后决定因素
Cancers (Basel). 2025 Feb 25;17(5):789. doi: 10.3390/cancers17050789.
2
Assessing frailty in myeloma: The pursuit of simplicity may sacrifice precision of predicting clinical outcomes.评估骨髓瘤中的衰弱：追求简单可能会牺牲预测临床结果的准确性。
Hemasphere. 2024 Jul 4;8(7):e85. doi: 10.1002/hem3.85. eCollection 2024 Jul.
3
Breaking through Multiple Myeloma: A Paradigm for a Comprehensive Tumor Ecosystem Targeting.

本文引用的文献

1
Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma.剂量/方案调整的 Rd-R 与连续 Rd 用于新诊断的老年、中危适合的多发性骨髓瘤患者。
Blood. 2021 Jun 3;137(22):3027-3036. doi: 10.1182/blood.2020009507.
2
Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial.来那度胺为基础的诱导和维持治疗老年初诊多发性骨髓瘤患者：EMN01 随机试验的更新结果。
Haematologica. 2020 Jul;105(7):1937-1947. doi: 10.3324/haematol.2019.226407. Epub 2019 Oct 3.
3
Approach to the Older Adult With Multiple Myeloma.
突破多发性骨髓瘤：一种全面靶向肿瘤生态系统的范例
Biomedicines. 2023 Jul 24;11(7):2087. doi: 10.3390/biomedicines11072087.
4
New Strategies for the Treatment of Older Myeloma Patients.老年骨髓瘤患者的治疗新策略
Cancers (Basel). 2023 May 10;15(10):2693. doi: 10.3390/cancers15102693.
5
The EHA Research Roadmap: Malignant Lymphoid Diseases.欧洲血液学协会研究路线图：恶性淋巴疾病
Hemasphere. 2022 May 19;6(6):e726. doi: 10.1097/HS9.0000000000000726. eCollection 2022 Jun.
6
Risk Stratification Before and During Treatment in Newly Diagnosed Multiple Myeloma: From Clinical Trials to the Real-World Setting.新诊断多发性骨髓瘤治疗前及治疗期间的风险分层：从临床试验到真实世界环境
Front Oncol. 2022 Mar 9;12:830922. doi: 10.3389/fonc.2022.830922. eCollection 2022.
老年多发性骨髓瘤的治疗方法
Am Soc Clin Oncol Educ Book. 2019 Jan;39:500-518. doi: 10.1200/EDBK_239067. Epub 2019 May 17.
4
Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis.初诊时接受第一代新型药物沙利度胺、来那度胺、硼替佐米治疗的骨髓瘤患者的早期死亡率：一项汇总分析。
Crit Rev Oncol Hematol. 2018 Oct;130:27-35. doi: 10.1016/j.critrevonc.2018.07.003. Epub 2018 Jul 18.
5
Determining treatment intensity in elderly patients with multiple myeloma.确定老年多发性骨髓瘤患者的治疗强度。
Expert Rev Anticancer Ther. 2018 Sep;18(9):917-930. doi: 10.1080/14737140.2018.1496823. Epub 2018 Jul 13.
6
Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN).老年骨髓瘤患者以患者为中心的治疗实践：来自欧洲骨髓瘤网络（EMN）的概述和共识。
Leukemia. 2018 Aug;32(8):1697-1712. doi: 10.1038/s41375-018-0142-9. Epub 2018 Apr 25.
7
A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma.一项针对未经治疗的老年虚弱多发性骨髓瘤患者的三种低剂量皮下硼替佐米方案的 2 期研究。
Leukemia. 2016 Jun;30(6):1320-6. doi: 10.1038/leu.2016.36. Epub 2016 Feb 22.
8
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report.老年评估可预测老年骨髓瘤患者的生存率和毒性：国际骨髓瘤工作组报告
Blood. 2015 Mar 26;125(13):2068-74. doi: 10.1182/blood-2014-12-615187. Epub 2015 Jan 27.
9
Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study.卡非佐米、环磷酰胺和地塞米松治疗新诊断多发性骨髓瘤患者的多中心、2 期研究。
Blood. 2014 Jul 3;124(1):63-9. doi: 10.1182/blood-2014-03-563759. Epub 2014 May 22.